Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Cadrenal Therapeutics, Inc. Common Stock, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Valuation | ||||
| P/E Ratio | -1.02x | -1.66x | -1.15x | -7.14x |
| P/B Ratio | 4.94x | 2.38x | 1.25x | -8.64x |
| P/S Ratio | 0.00x | 0.00x | 0.00x | 0.00x |
| Profitability | ||||
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 0.0% | 0.0% | 0.0% |
| Liquidity | ||||
| Current Ratio | 2.72x | 3.77x | 10.27x | 0.55x |
| Quick Ratio | 2.72x | 3.77x | 10.27x | 0.55x |
| Leverage | ||||
| Debt/Equity | 0.00x | 0.00x | 0.00x | -0.12x |
YoY = year-over-year change. Source: FMP..